Navigation Links
Endocare Reports Financial Results for Second Quarter 2008

Net Revenues Equal to Prior Year and Net Losses Narrowed Compared to Prior


IRVINE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, today reported that despite flat year-over-year revenue, net losses narrowed year-over-year on higher gross margin during the second quarter ended June 30, 2008.

Total revenues for the second quarter of 2008 were $7.9 million, equal to the second quarter of 2007. Domestic probe sales, as well as the estimated number of domestic cryoablation procedures performed, in the second quarter and the first six months of 2008 and 2007 are summarized in the following table:

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Estimated domestic cryoablation

procedures 2,292 2,435 4,860 4,750

Number of cryoprobes sold:

Straight probes 9,074 10,131 19,357 19,895

Right-angle probes 2,054 1,626 3,974 3,073

Total 11,128 11,757 23,331 22,968

Probe sales are reported in two categories: straight probes, which are typically, although not always, used in prostate procedures and right-angle probes, which are typically used in procedures other than prostate procedures.

Gross margin in the second quarter of433 10,919

Total liabilities and stockholders' equity $17,804 $21,261

2008 increased to 70.4 percent, compared to 65.7 percent in the second quarter of 2007. Gross margin continued to increase from production efficiencies and reductions in materials costs. Operating expenses in the second quarter of 2008 were $7.7 million, compared to $7.6 million in the second quarter of 2007.

Endocare Chairman, CEO and President Craig T. Davenport said, "While cryoablation continues to show clinical equivalency and in some cases superiority to radiation and other treatment options, competitive procedures and their associated economics led to some dilution with existing physician customers in the first half of the year. A thorough review of our year-to-date performance -- including the number and types of cases performed by each of our physician customers -- suggested that urology prostate cancer cases were impacted primarily by the emergence of robotic prostatectomy and intensity modulated radiation therapy (IMRT). We believe that patient demand for robotics and the current opportunity for greater financial benefits to the physician from IMRT have specifically led to that dilution. While the growth in non-prostate applications continues to show strength, the decline in the number of prostate procedures is being addressed in an aggressive manner."

Davenport continued, "We already have taken steps to help us regain the growth that we have demonstrated in the past. These steps include programs intended to impact the number of new physicians trained, increase revenues from our existing customers and communicate directly and more broadly with patients to educate them about the significant benefits of cryoablation. The programs include additional new urology sales personnel, significantly enhanced patient outreach and advertising and programs that assist our existing physician customers in reaching more patients through community-based marketing. An important element of these programs is an increased emphasis on focal cryoablation, since we believe that this is an area where we have a potentially substantial competitive advantage."

Net loss for the second quarter of 2008 was $2.0 million, or $0.17 loss per share, compared to a net loss of $2.3 million, or $0.21 loss per share, in the second quarter of 2007. Included in the net loss for the second quarter was $828,000 of legal expenses related to the legal proceedings of the Company's former CEO and former CFO, compared to a credit (a reduction of expense) of $280,000 from refunded legal expenses in the second quarter of 2007.

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) was a loss of $1.1 million for the second quarter of 2008, equal to a loss of $1.1 million for the second quarter of 2007. A reconciliation of the differences between the GAAP net losses and the adjusted EBITDA losses is included in an accompanying table.

Chief Financial Officer Michael Rodriguez reported cash and cash equivalents of $4.8 million, total assets of $17.8 million, and total stockholders' equity of $8.4 million as of June 30, 2008. The Company also has potentially up to $5.0 million in additional capital available under the stock purchase agreement announced in October 2006, depending on its prevailing stock price, as well as amounts available on its credit facility with Silicon Valley Bank. Rodriguez added that, in light of the investments required to fund the growth initiatives described above as well as the ongoing legal proceedings referred to above, the Company continues to assess the adequacy of its capital resources and may use both existing and new sources of capital to finance the growth of the business.

Conference Call

As previously announced, Endocare will host a conference call today to discuss the Company's results for its second quarter ended June 30, 2008. The call will take place at 11:00 a.m. (Eastern) and be broadcast live over the Internet. To participate on the call, dial 1-877-870-1962 for callers in the U.S. or +1-706-758-9692 for callers outside the U.S. Web participants are encouraged to go to the Company's website ( at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The online archived replay will be available immediately following the conference call at

Use of Non-GAAP Financial Measures

The Company uses, and this press release contains and the related conference call will include, the non-GAAP metric of adjusted EBITDA. The calculation of adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and also excluding FASB 123R non-cash stock compensation expense, collectively "adjusted EBITDA") has no basis in GAAP. The Company's management believes that this non-GAAP financial measure provides useful information to investors, permitting a better evaluation of the Company's ongoing and underlying business performance, including the evaluation of its performance against its competitors in the healthcare industry. Management uses this non-GAAP financial measure for purposes of its internal projections and to evaluate the Company's financial performance.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by the Company may not be comparable to similarly titled amounts reported by other companies. A complete reconciliation of this non-GAAP financial measure for the applicable periods to the most directly comparable GAAP measures is presented in an accompanying table.

About Endocare

Endocare, Inc. -- -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, the following items: the Company may incur significant expenses in the future as a result of the Company's obligation to pay legal fees for and otherwise indemnify former officers and former directors in connection with the ongoing investigations and legal proceedings involving them; uncertainty relating to third party reimbursement; the Company has a limited operating history with significant losses and losses may continue in the future; the Company may require additional financing to sustain its operations and without it the Company may not be able to continue operations; the sale of the Company's common stock to Fusion Capital may cause dilution, and the sale of the shares of common stock acquired by Fusion Capital or Frazier Healthcare Ventures could cause the price of the Company's common stock to decline; the Company's business may be materially and adversely impacted by the loss of the Company's largest customer or the reduction, delay or cancellation of orders from this customer or if this customer delays payment or fails to make payment; the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; the risk that intense competition and rapid technological and industry change may make it more difficult for the Company to achieve significant market penetration; and uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400





(In thousands, except for per share data)

Three Months Ended June 30,

2008 2007

Total revenues $7,930 $7,901

Costs and expenses:

Cost of revenues 2,347 2,713

Research and development 570 621

Selling and marketing 3,869 4,099

General and administrative 3,243 2,845

Total costs and expenses 10,029 10,278

Loss from operations (2,099) (2,377)

Interest income, net 67 113

Net loss $(2,032) $(2,264)

Net loss per share - basic and diluted $(0.17) $(0.21)

Weighted average shares of common stock outstanding 11,802 10,916




(In thousands, except for per share data)

Six Months Ended June 30,

2008 2007

Total revenues $16,073 $15,447

Costs and expenses:

Cost of revenues 4,852 5,335

Research and development 1,138 1,236

Selling and marketing 7,697 7,862

General and administrative 6,283 6,674

Total costs and expenses 19,970 21,107

Loss from operations (3,897) (5,660)

Interest income, net 176 139

Net loss $(3,721) $(5,521)

Net loss per share - basic and diluted:

Continuing operations $(0.32) $(0.52)

Weighted average shares of common stock outstanding 11,794 10,618






(In thousands)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

GAAP net loss $(2,032) $(2,264) $(3,721) $(5,521)


Depreciation 127 145 253 327

Amortization of intangibles 125 158 251 285

Interest expense 32 54 63 110

Subtotal (1,748) (1,907) (3,154) (4,799)

Add: Stock compensation expense 698 794 1,426 1,584

Adjusted EBITDA $(1,050) $(1,113) $(1,728) $(3,215)



(In thousands, except for per share data)

June 30, December 31,

2008 2007



Current assets:

Cash and cash equivalents $4,804 $7,712

Accounts receivable, net 4,494 3,530

Inventories, net 3,286 3,022

Prepaid expenses and other current assets 520 2,081

Total current assets 13,104 16,345

Property and equipment, net 839 850

Intangibles, net 2,827 3,077

Investments and other assets 1,034 989

Total assets $17,804 $21,261


Current liabilities:

Accounts payable $3,028 $2,194

Accrued compensation 2,090 3,895

Other accrued liabilities 3,039 3,034

Line of credit 880 880

Capital lease obligation, current portion 25 28

Total current liabilities 9,062 10,031

Capital lease obligation 75 84

Deferred compensation 234 227

Stockholders' equity:

Preferred stock, $0.001 par value; 1,000 shares

authorized; none issued and outstanding - -

Common stock, $0.001 par value; 50,000 shares

authorized; 11,806 and 11,762 issued and

outstanding as of June 30, 2008 and December 31,

2007, respectively 12 12

Additional paid-in capital 201,898 200,663

Accumulated deficit (193,477) (189,756)

Total stockholders' equity 8,

SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
2. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
3. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
4. Endocare Reports 2007 Third Quarter and Nine-Month Results
5. Endocare Stock to Commence Trading on NASDAQ
6. P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth
7. Metropolitan Health Networks Reports 2008 Second Quarter Results
8. NxStage Reports Second Quarter 2008 Financial Results
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Stereotaxis Reports Record Second Quarter Revenue
11. Vion Reports 2008 Second Quarter and Six-Month Results
Post Your Comments:
(Date:10/13/2017)... ... 2017 , ... While it’s often important to take certain medications during the ... Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL ... it eliminates the need to turn on a light when taking medication during the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: